NCT03598257 2026-03-17
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03359954 2026-03-05
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04266249 2026-03-02
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02927912 2026-02-17
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04683679 2026-02-17
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07188246 2026-02-11
BRINK
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Recruiting
NCT02912312 2026-01-07
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06492759 2025-12-16
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Not yet recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04690855 2023-12-04
TARA
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02538471 2019-12-09
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00376805 2017-12-28
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02203565 2017-07-26
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Stanford University
Phase 2 Completed
NCT00003199 2017-07-12
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT01754519 2017-07-07
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT00119262 2014-05-15
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed